Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

30,397292,193Patent filing fees, net

807,357701,846Other assets

59,56875,394Total assets$
8,750,079$
4,086,177LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIESAccounts payable and accrued expenses 

$
,199,662$
,843,684Accrued bonus expense

465,865582,675Other current liabilities

90,776-Total current liabilities1,756,3032,426,359Deferred rent, net of current portion

21,143-Total liabilities

1,777,4462,426,359STOCKHOLDERS' EQUITYPreferred stock, 7,000,000 shares authorized, zero shares issued and outstanding

--Common stock, $0.01 par value; 150 million shares authorized,  68,189,314 and 48,682,118 shares outstanding in 2012 and 2011,respectively

681,893486,821Additional paid-in capital

114,884,91599,645,655Accumulated deficit

(108,594,175)(98,472,658)Total stockholders' equity6,972,6331,659,818Total liabilities and stockholders' equity$
8,750,079$
4,086,177 Neuralstem, Inc.Statements of OperationsYear Ended December 31,20122011Revenues

$
407,708$
390,625Operating expenses:Research and development costs

6,105,9847,354,857General and administrative expenses

4,247,0375,839,188Depreciation and amortization

211,143187,050Total operating expenses

10,564,16413,381,095Operating loss

(10,156,456)(12,990,470)Other income (expense):Litigation settlement

3,484250,000Interest income

34,15460,955Interest expense

(2,699)(821)Gain from change in fair value of warrant obligations

-161,809Total other income (expense) 

34,939471,943Net loss

$
(10,121,517)$
(12,518,527)Net loss per share - basic and diluted

$
(0.17)$
(0.26)Weighted average common shares outstanding - basic and diluted

58,153,92948,340,557 

About Neuralstem

Neuralstem's patented technology enables the ability to produce n
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... ... 27, 2015 , ... Inc. Magazine released its annual list of the 5,000 ... in growth for the three years through 2014. Being named to the Inc. 5000 ... in the country. , “We are thrilled to make the Inc. 5000 list ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... here is expanding to produce more trillions of beneficial ... clean up soil and groundwater, treat waste water, and ... its output this year from about 20,000 gallons a ... -- about 1.1 trillion per gallon. The production increase ...
... /PRNewswire/ -- US Oncology, Inc ., one ... to FORTUNE magazine,s Most Admired Companies list ... and Other category. This is the third time US Oncology has ... Most Admired Companies distinction, having been named to the list in ...
... the viability of Embryonic Stem Cells is an Illusion. Repair (Adult) ... treated all over the world, that it will be impossible for embryonic ... ever. , ... Bangkok (PRWEB) March 12, 2009 -- Don Margolis, the ...
Cached Biology Technology:Osprey Biotechnics: More Trillions of Good Bacteria 2US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time 2US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time 3Repair Stem Cell Institute Weighs in on Reversal of Embryonic Stem Cell Policy 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... like hype from a late-night infomercial: It can twist ... could someday help you fend off disease! But ... several institutions including the U.S. Department of Energy,s Lawrence ... the cell,s protein-making machine, the ribosome, at key stages ...
... available in Spanish . , After corn ... looks something like slightly dampened cornmeal, though a somewhat darker ... grains with solubles" (WDGS), this byproduct is sometimes used as ... in Clay Center, Neb., are studying the pros and cons ...
... Researchers from the University of Iowa Roy J. ... that inhaled carbon black nanoparticles create a double source ... published online in the April 27 edition of the ... UI professor of internal medicine, was lead author of ...
Cached Biology News:Atomic-scale structures of ribosome could help improve antibiotics 2Atomic-scale structures of ribosome could help improve antibiotics 3Studies focus on feed ingredient's effects on levels of E. coli O157:H7 in cattle 2Carbon black nanoparticles can cause cell death 2
Edited by Benjamin Lewin (1997) • This book gives an integrated account of the structure and function of genes in both prokaryotic organisms and is thoroughly up to date with the latest thinking...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
...
Applications: ISH...
Biology Products: